Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoterMichael Lim, Antonio Omuro, Michael Weller et al.|Neuro-Oncology|2022Cited by 508
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548Michael Weller, Antonio Omuro, Michael Lim et al.|Neuro-Oncology|2021Cited by 29
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.Martijn P. Lolkema, Sarah P. Blagden, E. Jansen et al.|Journal of Clinical Oncology|2019Cited by 1